Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Active, not recruiting

Plain-English translation of NCT03734029 on ClinicalTrials.gov ↗ · Source last updated October 2025 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(208 sites)

United States

Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona

Banner MD Anderson Cancer Center, Gilbert, Arizona

Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona

UCLA School of Medicine, Los Angeles, California

Stanford Cancer Institute, Palo Alto, California